Paper32158481
Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.
Galbiati D and 10 others. Drugs Context, 2019. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Papers, record 32158481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32158481
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31051028 | Systemic therapy for advanced cutaneous squamous cell carcinoma. | Semin Cutan Med Surg | 2019 | https://conductscience.org/library/papers/31051028 | PubMed |
| 2 | 22484186 | Chemotherapy of squamous cell carcinoma of the skin. | Semin Oncol | 2012 | https://conductscience.org/library/papers/22484186 | PubMed |
| 3 | 25716064 | Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review. | Australas J Dermatol | 2015 | https://conductscience.org/library/papers/25716064 | PubMed |
| 4 | 15865067 | Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. | Anticancer Res | 2005 | https://conductscience.org/library/papers/15865067 | PubMed |
| 5 | 11274625 | Cutaneous squamous-cell carcinoma. | N Engl J Med | 2001 | https://conductscience.org/library/papers/11274625 | PubMed |
| 6 | 29734047 | Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. | Eur J Cancer | 2018 | https://conductscience.org/library/papers/29734047 | PubMed |
| 7 | 31163235 | Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. | J Am Acad Dermatol | 2020 | https://conductscience.org/library/papers/31163235 | PubMed |
| 8 | 31587382 | Stage IV cutaneous squamous cell carcinoma: treatment outcomes in a series of 42 patients. | J Eur Acad Dermatol Venereol | 2020 | https://conductscience.org/library/papers/31587382 | PubMed |
| 9 | 30672860 | Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. | Dermatol Surg | 2019 | https://conductscience.org/library/papers/30672860 | PubMed |
| 10 | 2004320 | Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. | Cancer | 1991 | https://conductscience.org/library/papers/2004320 | PubMed |
| 11 | 22592943 | The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. | J Surg Oncol | 2012 | https://conductscience.org/library/papers/22592943 | PubMed |
| 12 | 28384639 | Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients. | Dermatology | 2016 | https://conductscience.org/library/papers/28384639 | PubMed |
| 13 | 29957662 | Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab. | Dermatol Surg | 2019 | https://conductscience.org/library/papers/29957662 | PubMed |
| 14 | 1698529 | Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. | Cancer | 1990 | https://conductscience.org/library/papers/1698529 | PubMed |
| 15 | 10776981 | Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. | Am J Clin Oncol | 2000 | https://conductscience.org/library/papers/10776981 | PubMed |
| 16 | 22534799 | Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma. | Int J Clin Oncol | 2013 | https://conductscience.org/library/papers/22534799 | PubMed |
| 17 | 6326362 | Diagnosis of human tumors. Case 10: Pseudosarcomatous squamous cell carcinoma. | Ultrastruct Pathol | 1983 | https://conductscience.org/library/papers/6326362 | PubMed |
| 18 | 22251204 | A systematic review of worldwide incidence of nonmelanoma skin cancer. | Br J Dermatol | 2012 | https://conductscience.org/library/papers/22251204 | PubMed |
| 19 | 29579331 | Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. | Cancer | 2018 | https://conductscience.org/library/papers/29579331 | PubMed |
| 20 | 22360041 | Cutaneous squamous cell carcinoma associated with proliferation of osteoclast-like giant cells. | J Pak Med Assoc | 2011 | https://conductscience.org/library/papers/22360041 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41333481 | Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41333481 | PubMed |
| 40632444 | The Role of Cetuximab in Non-Melanoma Skin Cancer: A Review of Clinical Evidence and Emerging Strategies. | Curr Treat Options Oncol | 2025 | https://conductscience.org/library/papers/40632444 | PubMed |
| 39072317 | Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab). | Front Immunol | 2024 | https://conductscience.org/library/papers/39072317 | PubMed |
| 35408839 | Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35408839 | PubMed |
| 35158897 | Update on Management Recommendations for Advanced Cutaneous Squamous Cell Carcinoma. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35158897 | PubMed |
| 34877077 | Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma. | Dermatol Pract Concept | 2021 | https://conductscience.org/library/papers/34877077 | PubMed |
| 32911687 | The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/32911687 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32158481
GET https://conductscience.org/api/papers/v1/32158481/references?page=2